Timmune has developed the proprietary TriTE (Tri-functional T cell Engager) technology, a co-expressed fusion protein platform T cell redirected cancer immunotherapy.
TriTE is a fusion protein platform with unique binding, T cell engaging, and stimulating features including:
R1: antigen binding domain, replaceable with our arsenal of single domain MAR constructs, or with other binding constructs
R2: anti-CD3 for T cell engaging and stimulating
R3 & R4: Sushi domain and IL15 binding pair, wherein IL15 also serves as a T cell stimulator
R5: PD1 for binding to PD-L1 on the cancer cell to block the T cell inhibitory pathway.
for cancer immunotherapy
1) PD1 blocks the PD-L1/PD1 pathway.
Easy to purify
Binding to both Protein L and Protein A